Uterine Fibroids Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Hormone Therapy is the fastest growing sector, North America is the largest market

The Global Uterine Fibroids Treatment Market is projected to grow from USD 5.15 billion in 2025 to USD 8.42 billion by 2031, achieving an 8.54% CAGR. As it centers on the therapeutic management of benign uterine tumors called leiomyomas. Market growth is primarily driven by the increasing demand for minimally invasive procedures that preserve fertility and reduce recovery times, such as uterine fibroid embolization and laparoscopic myomectomy. Further advancements in robotic surgical systems and the introduction of novel pharmacological therapies are expanding the treatment landscape, offering viable alternatives to traditional open surgeries. However, a significant barrier remains the lack of patient awareness regarding alternative therapies and a historical over-reliance on major surgery, evidenced by a 2024 survey where 53% of women were primarily offered a hysterectomy, limiting access to modern interventions.

Market Drivers

Key drivers for market expansion include significant advancements in minimally invasive surgical techniques, which are fundamentally reshaping treatment by offering effective uterine-sparing alternatives to traditional hysterectomies. Patients' increasing preference for procedures like radiofrequency ablation and hysteroscopic morcellation, which minimize recovery time and preserve fertility, is fueling industry consolidation and investment in novel device platforms, as seen with Hologic's $350 million acquisition of Gynesonics. Concurrently, the commercialization of novel GnRH antagonists is broadening the therapeutic landscape for non-surgical management. These oral pharmacotherapies effectively control heavy menstrual bleeding and reduce fibroid volume, addressing a critical gap for women ineligible for or averse to surgery, with treatments like Myfembree showing a 32% year-over-year revenue increase, crucial amidst a rising global incidence rate of uterine fibroids reaching 250.93 per 100,000 women.

Market Challenges

A major impediment to the growth of the Global Uterine Fibroids Treatment Market is the persistent lack of patient awareness regarding alternative therapies, coupled with a historical over-reliance on major surgery. This information asymmetry leads to a continued preference for radical surgical interventions like hysterectomies, thereby removing patients from the addressable market for fertility-preserving devices and long-term management therapies. Consequently, manufacturers of non-surgical solutions face substantial difficulty in market penetration and achieving projected revenue targets. This challenge is underscored by a 2024 survey from the Society of Interventional Radiology, which indicated that 17% of women mistakenly believed a hysterectomy was the only available treatment, directly hindering demand for less invasive options like uterine fibroid embolization and underutilizing the market potential for emerging therapeutic segments.

Market Trends

Notable market trends include advancements in image-guided non-invasive ablation technologies, which are establishing a new therapeutic class distinct from traditional minimally invasive surgery. Technologies such as Magnetic Resonance-guided Focused Ultrasound (MRgFUS) use high-intensity sound waves to destroy fibroid tissue through intact skin, offering a completely non-invasive approach that preserves uterine integrity and eliminates surgical recovery time, appealing to patients seeking fertility-sparing options without surgical risks. The rapid clinical acceptance of this incision-less modality is highlighted by uterine fibroids being a leading indication among over one million patients treated with focused ultrasound technologies worldwide in 2025. Additionally, the migration of procedures to outpatient and ambulatory surgical settings is reshaping service delivery, driven by payer incentives for cost reduction and the availability of office-ready devices, leading to increased utilization of systems like MyoSure and Sonata in outpatient gynecological facilities, contributing to robust revenue growth for companies like Hologic.

Key Market Players

• Gynesonics Inc.
• Medtronic Plc.
• Boston Scientific Corporation
• Karl Storz Gmbh
• Pfizer Inc.
• Abbvie Inc.
• Richard Wolf GmbH
• CooperSurgical Inc.
• Olympus Corporation
• Myovant Sciences GmbH

Report Scope

In this report, the Global Uterine Fibroids Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Uterine Fibroids Treatment Market, by Type:

• Subserosal Fibroids
• Intramural Fibroids
• Submucosal Fibroids
• Pedunculated Fibroids

Uterine Fibroids Treatment Market, by Treatment:

• Hormone Therapy
• Androgens
• Gonadotropin-Releasing Hormone Antagonists
• Uterine Artery Embolization
• Myomectomy
• Hysterectomy

Uterine Fibroids Treatment Market, by End-User:

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Uterine Fibroids Treatment Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Uterine Fibroids Treatment Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.